Gaucher disease: a strategic collaborative approach from the European Medicines Agency and Food and Drug Administration

  • Email
  • Help
Current version

Adopted collaborative approach

Reference numberEMA/237265/2017
Published30/06/2017
KeywordsGaucher disease, lysosomal storage disorder, enzyme replacement therapy, substrate-reduction therapy
DescriptionThis document aims to increase the chances of rapid and smooth agreement of the paediatric investigation plan (EMA)/pediatric study plan (FDA). It also discusses the possibility of a multi-arm, multi-company clinical trial for the treatment of Gaucher disease, as one approach to address the feasibility of developing multiple products for a rare disease in a limited timeframe.


Document history

First version

Current version

Adopted collaborative approach


 

 

Overview of comments


Draft collaborative approach

Published: 30/06/2017

 

In operation: 30/06/2017-present


Published: 30/06/2017


Published: 14/05/2014

 

How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more